Loading
Life sciences · Journal article
Molecular Cancer · November 6, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Antibody-drug conjugates (ADCs) are targeted therapeutic agents formed by covalently linking monoclonal antibodies to potent cytotoxic drugs via chemical linkers. They achieve targeted delivery of cytotoxic drugs through the antibody’s specific recognition of tumor surface antigens, enhancing antitumor activity while significantly reducing systemic toxicity. They are hailed as “biological missiles.” In recent years, with the advancement of ADCs, they have demonstrated remarkable efficacy in multiple clinical studies for solid tumors such as breast cancer, lung cancer, and urothelial carcinoma. They are progressively becoming an integral part of standard treatment regimens for various advanced cancers. However, the clinical application of ADCs still faces numerous challenges, including therapeutic variability due to heterogeneous expression of target antigens, the gradual emergence of resistance mechanisms (such as target downregulation, lysosomal dysfunction, and activation of drug efflux pumps), and unique toxicity profiles (such as ocular toxicity and hematologic toxicity). Furthermore, the therapeutic window for ADCs remains relatively narrow, and significant inter-individual pharmacokinetic variability further limits their widespread adoption. This review systematically elucidates the mechanisms of action and structural basis of ADCs, summarizes their clinical practice and evolving indications in solid tumors, analyzes the mechanisms and management strategies for common and specific adverse events, and thoroughly explores the molecular pathways underlying resistance development and corresponding countermeasures. This review further focuses on the technological development directions of the new generation of ADCs, including targeted conjugation strategies, the development of novel linker-payload systems, the construction of bispecific ADCs, and advances in combination therapies involving ADCs with immunotherapy and targeted drugs in order to provide new insights for overcoming existing clinical bottlenecks.